4.6 Article

Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia

Related references

Note: Only part of the references are listed.
Article Critical Care Medicine

High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats

Satoshi Hagiwara et al.

INTENSIVE CARE MEDICINE (2008)

Article Hematology

High-mobility group box 1 protein promotes development of microvascular thrombosis in rats

T. Ito et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)

Review Infectious Diseases

The role of high mobility group box-1 protein in severe sepsis

Jonas Sunden-Cullberg et al.

CURRENT OPINION IN INFECTIOUS DISEASES (2006)

Review Hematology

The interactions between inflammation and coagulation

CT Esmon

BRITISH JOURNAL OF HAEMATOLOGY (2005)

Article Multidisciplinary Sciences

Reversing established sepsis with antagonists of endogenous high-mobility group box 1

H Yang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)

Review Biochemistry & Molecular Biology

Novel strategies for the treatment of sepsis

NC Riedemann et al.

NATURE MEDICINE (2003)

Article Multidisciplinary Sciences

Release of chromatin protein HMGB1 by necrotic cells triggers inflammation

P Scaffidi et al.

NATURE (2002)

Article Medicine, General & Internal

High-dose a randomized antithrombin III in severe sepsis -: A randomized controlled trial

BL Warren et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)

Review Biochemistry & Molecular Biology

The double life of HMGB1 chromatin protein:: architectural factor and extracellular signal

S Müller et al.

EMBO JOURNAL (2001)